Atea Pharmaceuticals, Inc. (AVIR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Atea Pharmaceuticals (AVIR) Q1 2026: HCV Phase III Enrollment Reaches 95%, Securing Late-Stage Pipeline Momentum
  May 13, 2026
• Atea Pharmaceuticals (AVIR) Q4 2025: $302M Cash Extends Runway as Phase III HCV Readouts Approach
  March 06, 2026
• Atea Pharmaceuticals (AVIR) Q3 2025: Dual Mechanism Data Elevates HCV Differentiation, $329M Runway Secured
  November 13, 2025
• Atea Pharmaceuticals (AVIR) Q2 2025: $25M Buyback and Phase III HCV Trials Advance Toward $3B Market
  August 08, 2025
• Atea Pharmaceuticals (AVIR) Q2 2024: COVID Antiviral Rx Jumps 32% as HCV Pill Burden Halved
  August 07, 2024
• Atea Pharmaceuticals (AVIR) Q1 2024: Sunrise-3 Enrolls 2,295 Patients, Fast-Tracks COVID-19 Data Readout
  May 14, 2024
• Atea Pharmaceuticals (AVIR) Q4 2023: Sunrise-3 Enrollment Surpasses 1,400, Unlocking COVID and HCV Milestone Cadence
  February 28, 2024

Browse all companies